Clinical trial
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists…
NCT00189722 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00189722 |
|---|---|
| Title | Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Europe B.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma, Bronchial, Bronchial Asthma |
| Intervention type | Drug |
| Interventions | Tacrolimus |
| Enrollment | 160 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 17, 2008 |
| Countries | Czechia, Germany, Poland, Russia, Ukraine |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: